Cheng Zeng1,
Xiaoyi Yang1,
Lantian Wang2,
Huiling He1,
Zhe Tang1,2 
For correspondence:- Zhe Tang Email: 8xi@zju.edu.cn Tel:+8686971335
Accepted: 27 May 2023 Published: 30 June 2023
Citation: Zeng C, Yang X, Wang L, He H, Tang Z. Bioinformatics and experimental validation of mechanisms underlying lenvatinib therapy for hepatocellular carcinoma. Trop J Pharm Res 2023; 22(6):1271-1281 doi: 10.4314/tjpr.v22i6.17
© 2023 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..
Purpose: To investigate and validate the therapeutic targets of lenvatinib in hepatocellular carcinoma (HCC), using bioinformatics and in vitro experiments.
Methods: The potential core targets of lenvatinib were identified through screening and analysis of various databases. The core targets were validated using in vitro experiments.
Results: The results showed that lenvatinib significantly affected pro-survival signals of MAPK signaling pathway which activate and regulate a range of cellular activities. Molecular docking revealed that key proteins may be the key targets of lenvatinib in its systematic anti-tumor effect on HCC. Results from quantitative reverse transcription-polymerase chain reaction (qRT-PCR) revealed that lenvatinib regulated the ex
Conclusion: The findings of this investigation provide a new insight for further development of lenvatinib as a drug for HCC treatment.
Archives
News Updates
Fulltext in PDF